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Background: The polycomb group (PcG) family BMI1, acting downstream of the hedgehog (Hh) pathway, plays an
essential role in the self-renewal of haematopoietic, neural, and intestinal stem cells, and is dysregulated in many
types of cancer. Our recent report has demonstrated that Hh signalling activation can predict very earlier relapse of
oesophageal cancers. As data were not available on the clinical role of BMI1 expression in oesophageal cancers
after chemoradiotherapy (CRT), we analysed whether it could be also used to predict disease progression and
prognosis in oesophageal cancer patients undergoing trimodality therapy of preoperative CRT and
oesophagectomy.
Methods: Expressions of BMI1 and p16INK4A, a downstream target of PcG, were analysed in 78 patients with
histologically confirmed oesophageal squamous cell carcinoma (ESCC) after preoperative CRT by
immunohistochemical staining. The association of BMI1 and p16INK4A expression with clinicopathologic
characteristics was analysed by χ2-test. Survival analysis was carried out by the log-rank test using Kaplan-Meier
method.
Results: Among 78 ESCC patients, 24 patients (30.8%) showed BMI1 positivity, mainly localised in the nuclei of
tumour cells. Patients harbouring BMI1-positive tumour cells showed significantly poorer prognoses than those
without such cells or residual tumours (mean disease-free survival (DFS) time 16.8 vs 71.2 months; 3-yr DFS 13.3% vs
49.9%, P=0.002; mean OS time 21.8 vs 76.6 months; 3-yr OS 16.2% vs 54.9%, P=0.0005). There was no significant
correlation between p16INK4A expression and BMI1 expression.
Conclusions: Our study shows that BMI1 expression is a predictor of early relapse and poor prognosis in ESCC after
CRT. These findings suggest that BMI1 signal activation might be involved in promoting cancer regrowth and
progression after CRT, and might be indicative of emergence of ‘more aggressive’ cancer progenitor cells.
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Oesophageal cancer is a virulent malignancy that has a
high fatality rate once it progresses beyond disease Stage
I. The presence of lymph node metastasis and vascular
invasion as well as distant organ involvement leads to a
poor clinical outcome [1]. The optimal management of
oesophageal cancer is complicated because both global
and institutional standard therapies vary and patients
often need specific individual management strategies.
There are data to support multimodal approaches for
this disease. Surgery is considered the mainstay of
treatment for patients, especially those with locoregion-
ally confined oesophageal cancer. However, the 5-year
survival rate is generally 20–50%, mainly due to the high
rate of recurrence, even after curative surgery [1,2]. In
Japan, preoperative chemotherapy has been proven to be
associated with a better clinical outcome than post-
operative chemotherapy (randomised trial of the Japan
Esophageal Oncology Group, JCOG9907) [3]. Moreover,
preoperative chemoradiotherapy (CRT) has been accepted
as a first-line therapy in the Unites States [4]. Since 1996,
we have advocated a trimodal therapy, a combination of
radical surgery with preoperative CRT, and have reported
increased resectability, reduced incidence of both local re-
currence and distant metastasis, and better clinical out-
come for CRT responders [5]. However, the benefit of
preoperative CRT over chemotherapy alone has not yet
been established in Japan, and remains controversial in
Europe. Some clinical trials in the West have shown that
this preoperative strategy benefits only the 25% of
patients who show a pathological complete response (CR;
no cancer cells in the resected specimen), whereas the
remaining 75% present with CRT-resistant and highly ag-
gressive cancers with lymph node and distant metastases
[6,7]. High mortality from this disease after surgery is due
to the limited number of current therapies, and refrac-
toriness of the disease due to the emergence of therapy-
resistant cancer cells. Therefore, it is clearly imperative to
develop biomarkers for predicting recurrence and to im-
plement efficient treatments for preventing recurrence
after surgery.
Therapy-resistant cancer cells are thought to be the
founder population that causes patient relapse and subse-
quent metastasis. A recent ‘cancer stem cell’ concept has
suggested the existence of a small subpopulation of
tumour cells harbouring stem cell-like unique properties
of self-renewal, asymmetric division, and pluripotency. It
is thought that these ‘more aggressive’ cancer progenitor
cells, refractory to conventional therapy, survive the treat-
ment to later regenerate a tumour with increased resist-
ance to therapy [8]. To date, putative cancer stem cells
have been identified in various cancer types including
breast [9], lung [10], colon [11,12], and pancreatic cancer
[13]. To treat the patients who harbour these cancer stemcells, chemo(radio)therapy and/or molecular-targeted
therapy, which has power to kill these cells, is essential.
B-cell-specific Moloney murine leukaemia virus inte-
gration site 1 (Bmi1) was first identified by retroviral
insertional mutagenesis when assessing collaborating
oncogenes in Eμ-myc transgenic mice [14,15]. Bmi1 is a
transcriptional repressor that belongs to the polycomb
group (PcG) family of proteins involved in axial pattern-
ing, haematopoiesis, regulation of proliferation, and sen-
escence [16]. It has been shown to play a role in
sustaining self-renewing cell activity by repressing the
INK4A locus encoding p16INK4A and p19ARF, which are
capable of inducing growth arrest, cellular senescence
and apoptosis [17-19]. PcG proteins are known to mod-
ify the chromatin structure around their binding sites by
marking the chromatin of their target genes through
methylation at lysine 27 of histone H3; these sites in-
clude the promoters of many developmental regulator
genes, leading to gene repression [20]. Recent studies
have documented increased BMI1 expression in a variety
of human cancers, such as non-small cell lung cancers
[21], medulloblastomas [22], prostate carcinomas [23],
colorectal cancers [24], breast carcinomas [25], and
oesophageal squamous cell carcinomas (ESCCs) [26].
Furthermore, BMI1, as well as Gli-1 of the hedgehog
(Hh) pathway, has been shown to be a key regulator of
self-renewal in both normal and tumourigenic human
mammary stem cells [27]. In our recent study, we have
shown the clinical significance of Hh signal activation to
predict very earlier relapse and poorer prognosis in
patients with ESCC after CRT [28]. Hence, aberrant
BMI1 expression might also be involved in the charac-
teristics of the ‘more aggressive’ cancer cell population
after CRT, because BMI1 is thought to be a downstream
target in the Hh pathway in medulloblastoma [22].
No data are currently available on the role of BMI1, a
candidate downstream target of the Hh pathway, in
oesophageal cancer progression after CRT. In this study,
therefore, we retrospectively investigated the expression
of BMI1 protein in human oesophageal cancer tissues
and evaluated the clinical implications of aberrant BMI1




Between April 1996 and December 2005, 78 patients, 13
women and 65 men with a mean age of 62.0 years
(range, 38–78 years), with surgically excised oesophageal
cancer were studied at the Hyogo College of Medicine,
Japan. For preoperative CRT, chemotherapy consisted of
5-flurouracil (5-FU; 500 mg/m2 per day) administration
for a 120-h continuous intravenous (i.v.) infusion start-
ing on day 1, and cisplatin (CDDP; 15 mg/m2 per day)
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ously [28,29]. Concurrent radiation therapy was per-
formed after CDDP infusion on days 1–5 by using a
linear accelerator (Mevatron KD2, Siemens, Germany),
as described previously [5]. Chemotherapy was com-
bined with radiation therapy during the first week, and
then radiation therapy alone was repeated for the next
3 weeks (days 8–12, 15–19, and 22–26). The patients
received 20 fractions of 2 Gy/day for a total dose of
40 Gy. Surgery was usually performed 4–6 weeks after
the completion of CRT. After the surgery, monthly
follow-up at the outpatient clinic was scheduled. Other
relevant patient information was obtained from office
charts, hospital records, and telephone interviews. Prior
to the use of these clinical materials for investigation,
approval from the institutional ethics committee (Hyogo
College of Medicine) and informed consent from
patients were obtained.
Evaluation prior to surgery
Approximately 3–5 weeks after the completion of CRT,
patients underwent a complete staging workup. Patients
were defined to have clinical CR to CRT if no residual
tumour was detected by endoscopy and if no occurrence
of metastatic disease was identified on a computed tom-
ography (CT) scan evaluation.
Immunohistochemistry
ESCC tissue specimens obtained by surgical resection after
preoperative CRT were cut longitudinally, and fixed in
10% formalin-solution. The pieces of ESCC tissue were
processed using conventional procedures for paraffin em-
bedding, and cut into 5-μm thickness. Specimens were
heated for 20 min at 98°C in Target Retrieval Solution
pH 9 (S2368, DakoCytomation, Glostrup, Denmark) to fa-
cilitate antigen retrieval. They were then incubated with
mouse monoclonal antibody against human BMI1 (F6,
Upstate, Lake Placid, NY, USA, diluted 1:100 in Dako
REAL Antibody Diluent [S202230, Dako, Glostrup,
Denmark]), mouse monoclonal antibody against human
p16INK4A (F-12, Santa Cruz Biotechnology, Santa Cruz,
CA, USA, 1:250), and goat polyclonal antibody against
human Gli-1 (C-18, Santa Cruz Biotechnology, 1:500), and
sequentially with an anti-mouse immunoglobulin antibody
using ChemMate EnVision Kit (DakoCytomation). Immu-
noreacted cells were visualized with 3, 3’-diaminobenzi-
dine, and nuclei were lightly counterstained with
haematoxylin. Normal mouse immunoglobulin G (IgG)
was substituted for the primary antibody as a negative con-
trol. Sections were examined microscopically by two
pathologists of the authors (L.T. and T.T.) without prior
knowledge of clinicopathological features. Immunohisto-
chemical samples were graded by the presence of positively
stained tumour cells as follows: no specific staining or <5%tumour cells (−); ≥5% to <35% tumour cells (+); ≥35% to
<65% tumour cells (++); and ≥65% tumour cells (+++).
Statistical analysis
All statistical analyses were carried out using STATISTICA
statistical software, version 06 J (STATISTICA, Tulsa, OK,
USA). Overall survival (OS) was defined as the time from
initial diagnosis to either the patient’s death or the date of
the last available information on vital status. Disease-free
survival (DFS) was defined as the length of time after treat-
ment during which no cancer was found. In univariate ana-
lysis, the difference between the cumulative survival rates
of the patient groups was calculated by the log-rank test
for comparison using Kaplan-Meier survival curves.
P < 0.05 was considered statistically significant.
Retrospective studies generally utilise the same
archived materials several times. This study is about the
ongoing therapeutic strategy, and patient characteristics
were not the same as that described in the previous
study published in 2008 [28]. The present study includes
data of an additional 9 patients subjected to CRT after
the previous evaluation, leading to the updated univari-
ate analysis of prognostic factors for survivals. Supple-
mentary Gli-1 data used in contrast with BMI1 has been
re-evaluated for this study. Evaluation for each clinical
study was dealt with independently.
Results
Patient and tumour characteristics
The patient characteristics are summarised in Table 1. The
patient gender bias was male dominated (male: female =
65:13). The mean follow-up period was 30 months (range,
3–120 months). One patient was lost to follow-up. The
tumour histology was ESCC in all cases, with 75 tumours
(96.2%) originating in the thorax. On the basis of the
tumour-node-metastasis (TNM) system of the International
Union Against Cancer (UICC), stage II tumours were seen
in 30 patients (38.5%), stage III tumours were seen in 32
patients (41.0%), and stage IV tumours were seen in 16
patients (20.5%). In total, 34 patients (43.6%) had lymph
node metastasis at the time of diagnosis. All lesions before
CRT presented with a T3 or T4 extent of invasion. Three-
quarters of the patients had tumours that were between 6
and 8 cm in diameter. An M+ classification was described
in 12 tumours. Three patients had distant metastasis of
the liver. All patients experienced a disease-free period.
During the follow-up period, 17 patients (21.8%) devel-
oped local recurrence or residual tumours, ten patients
(12.8%) developed neck or celiac lymph-node recurrence,
and 14 patients (17.9%) developed distant metastasis. In
total, 41 patients (52.6%) died during follow-up; among
these, 33 patients (42.3%) died from their tumours, while
the remaining eight patients (10.3%) were tumour free and
died of intercurrent diseases.
Table 1 Patient characteristics
Characteristics n
Sex (Male/Female) 78 (65/13)
Mean age, years (range) 62.0 (38–76)














UICC: International Union against Cancer.
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Twenty-eight tumours were completely eradicated by
CRT, resulting in an absence of visible tumour cells: a
pathological CR. BMI1 immunostaining was diffuse and
granular, and predominantly localised in the nuclei ofFigure 1 Immunohistochemical detection of BMI1 in ESCC specimens
of BMI1 (B-1; ×10, B-2; ×40). Bars indicate 100 μm.ESCCs. BMI1 expression was absent from 26 tumours
and 28 eradicated regions but present in 24 tumours
(30.8%); 14 tumours (17.9%) were for grade (+), 8 (10.3%)
for (++), and 2 (2.6%) for (+++) (Figure 1). All eight can-
cers with Gli-1-positive nuclei expressed BMI1. In the
BMI1-positive group, recurrences were found in 18 out of
24 patients (75.0%); these were local in seven cases and
distant (in the liver, bone, lung and neck lymph nodes) in
11 cases. By contrast, in the BMI1-negative or no residual
tumour group (n = 54), recurrences were found in 24
patients (in the liver, bone, skin, neck lymph nodes and
thyroid gland); these were local in 16 cases and distant in
eight cases. Statistical analysis by χ2-test showed that
BMI1 positivity significantly correlates with T and N sta-
ging (P = 0.0137, and P = 0.0130, respectively) but not
with M staging (P = 0.755). According to the subanalysis,
distant recurrence was more common in patients positive
for BMI1 (P = 0.0084). The univariate analysis of the OS
prognostic factors is summarised in Table 2. Lymph node
metastasis, distant metastasis and depth of tumour inva-
sion all had significant prognostic value (P = 0.002,
P = 0.0001, and P = 0.0001, respectively). Furthermore,
patients showing an effect of CRT revealed significantly
better OS prognosis compared with those showing no ef-
fect (P = 0.0001).
Kaplan-Meier analysis suggested that the prognosis was
particularly unfavourable for patients with BMI1 positivity
in their primary tumours (Group III), compared with. A. Strong expression of BMI1 (A-1; ×10, A-2; ×40). B. Null expression





Age (years) ≥70 22 1.111 0.552-2.234 0.770
<70 56
Gender Male 65 0.312 0.096-1.016 0.023*
Female 13
Effect of CRT Effective 56 0.191 0.098-0.370 0.0001***
Not effective 22




Positive 12 3.988 2.001-7.947 0.0001***
Negative 66
Depth of tumour T3 40 0.308 0.157-0.602 0.0001***
invasion T4 38
Tumour location1 Upper 13 1.299 0.597-2.827 0.509
Lower 65
BMI1 expression positive 24 3.347 1.775-6.313 0.0001***
negative 54
1 Upper or lower: above or below the tracheal bifurcation.
*P<0.05; ** P<0.005; *** P<0.0005.
Figure 2 DFS curves and P-values (log-rank test) for comparisons amo
negative tumours (Group II), patients with no residual tumour and th
patients with BMI1-positive tumours (Group III).
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no residual tumour (pathological CR; Group I).
The mean DFS time in the BMI1-positive tumour group
(Group III) was 16.8 ± 4.5 months (95% CI 7.9–
25.7 months) compared with 71.2 ± 8.9 months (95% CI
53.9–88.6 months) in the BMI1-negative tumour group
and the no residual tumour group combined (Group I+II)
(Figure 2; P = 0.002); the mean OS times for these groups
were 21.8 ± 4.7 months (95% CI 15.8–61.5 months)
(Group III) and 76.6 ± 8.6 months (95% CI 59.8–
93.4 months) (Group I+II), respectively (Figure 3;
P = 0.0005). Furthermore, the BMI1-positive tumour
group (Group III) showed significantly shorter DFS and
OS times compared with the BMI1-negative tumour
group alone (Group II: Figure 2; mean DFS time 39.9 ±
8.6 months, 95% CI 23.0–56.8 months, P = 0.045, Fig-
ure 3; mean OS times 53.1 ± 7.9 months, 95% CI 37.5–
68.7 months, P = 0.006).
The 1-year and 3-year DFS rates in the BMI1-positive
group (Group III) were 31.1% and 13.3% respectively.
Those in the BMI1-negative tumour group (Group II)
were 57.8% and 38.5%, while those in the BMI1-negative
and no residual tumour groups combined (Group I+II)
were 68.6% and 49.9%, respectively. The corresponding
1-year and 3-year OS rates were 59.3% and 16%,ng patients with no residual tumour (Group I), those with BMI1-
ose with BMI1-negative tumours combined (Group I+II), and
Figure 3 OS curves and P-values (log-rank test) for comparisons among patients with no residual tumour (Group I), those with BMI1-
negative tumours (Group II), patients with no residual tumour and those with BMI1-negative tumours combined (Group I+II), and
patients with BMI1-positive tumours (Group III).
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in Group II, and 87.2% and 54.9%, respectively, in Group
I+II.
Correlation between BMI1 and p16INK4A
The protein p16INK4A was considered to be present when
nuclear and/or cytoplasmic staining was detectable. Of 78
ESCC patients subjected to CRT, 55.2% were completely
negative (category 0), 25.6% were weakly positive (cat-
egory I, 5-50% positive cells) and 19.2% were strongly
positive (category II, 51-100% positive cells). Statistical
analysis by χ2-test showed that p16INK4A positivity was
not correlated with BMI1 positivity (P = 0.7662). Further-
more, there was no correlation between p16INK4A positiv-
ity and prognosis in BMI1-positive tumours (P = 0.4602).
Discussion
We have shown that persistent expression of the chemo-
kine receptor CXCR4 and Hh signal activation can pre-
dict very earlier relapse and poorer prognosis in ESCC
patients after CRT [28,30]. Our findings suggest that stem
cell renewal factors are, at least in part, but critically,
involved in recurrent and metastatic behaviour under the
microenvironment (niche) around the surfaces of tumourcells, in response to external therapeutic intervention (for
example, CRT). Additionally, the current study has
revealed that expression of BMI1 protein along with Hh
signal activation might be a useful and reliable biomarker
for the screening and management of high-risk patients
with poorer prognosis after CRT. In the patients with
BMI1-negative tumours, postoperative chemotherapy
seemed to prolong the survival time to the same level
achieved in the no residual tumour group, even after the
diagnosis of a recurrence. Glinsky et al. demonstrated
that tumours displaying a stem cell-like expression profile,
namely, an 11 BMI1 oncogene-driven gene signature,
have a significantly higher probability of developing dis-
tant metastasis within five years after therapy in five epi-
thelial malignancies (prostate, breast, lung, ovarian, and
bladder cancers) and five non-epithelial malignancies such
as lymphoma [23], and that the CD44+/CD24- blood-
borne human prostate carcinoma metastasis precursor
cell population contains a large proportion of cancer cells
with high-level coamplification of both BMI1 and Ezh2
PcG genes [31]. A growing body of preclinical and clinical
evidence is accumulating to show the significance of
BMI1 in chemoresistance and recurrence [32]. Taken to-
gether, these data strongly support the possibility of a
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and manifestation of various clinically lethal, therapy-
resistant cancer phenotypes. Intriguingly, 70.8% of BMI1-
positive tumours in the present study also expressed
CD44 strongly (data not shown). In the terminal stage,
the network of stem cell surface markers implicating can-
cer progenitor cells might epigenetically contribute to
cancer relapse and treatment failure.
To date, there has been no specific decision-making
strategy in clinical management for oesophageal cancer
patients after CRT. Immunohistochemical analysis of
BMI1 and/or Gli-1 in all post-CRT ESCC patients seems
highly informative and convenient in the stratification of
patients into subgroups with a distinct likelihood of
therapy failure. In some cases, supportive care emphasis-
ing quality of life rather than aggressive anti-cancer ther-
apy might be recommended, or a pioneering clinical trial
utilising Hh-PcG chromatin-silencing pathways blockade
should be prioritised in high-risk patients. Despite the
recent advances in oesophageal cancer treatment, the
fact remains that clinicians continue to face the chal-
lenge of frequent recurrence or metastasis relating to
CRT-resistant ‘more aggressive’ cancer cells after sur-
gery. Namely, it is suggested that the limitation of
present therapies is likely to relate to their inability to
target the cancer stem cell component, and that now is
the time for a paradigm shift in anti-cancer strategy.
Sims-Mourtada et al. demonstrated in vitro that Hh-
induced chemoresistance through multiple drug trans-
porter mechanisms can be overcome by inhibitors of the
Hh pathway [33]. Furthermore, Berezovska et al. showed
potential therapeutic efficacy of the siRNA-mediated tar-
geting of BMI1 expression, in vitro and in vivo, for treat-
ing metastatic prostate cancer [34]. When the molecular
mediators of therapeutic resistance by cancer stem cells
are established, developing clinically efficient and safe
inhibitors to target these pathways, focusing on Hh-PcG
pathway activation, would definitely be of benefit for the
treatment of high-risk patients.
In this study, we also found no correlation between
BMI1 positivity and p16INK4A positivity. In contrast to
the results of our study, BMI1-mediated regression of
p16INK4A has been reported to contribute to an increased
incidence of metastasis in melanoma patients [35].
Furthermore, the loss of p16INK4A gene expression,
mainly caused by frequent p16INK4A promoter methyla-
tion, is known to have a strong relationship with poor
prognosis in ESCC patients [36]. The contradictory
result of no direct linking between BMI1 and down-
stream p16INK4A in this study may be mainly due to the
effects of therapeutic intervention. CRT can be assumed
to cause G1-S phase cell cycle alteration which could
interfere in the regression of p16INK4A, involving ‘more
aggressive’ cancer cells per se and their indispensablemicroenvironment niche. Thus, in ESCC patients
subjected to CRT, the role of BMI1-mediated inhibition
of p16INK4A protein is not clear, and the clinical effect of
Hh signalling pathway activation might be more evident
than that of the presence of BMI1, whilst BMI1and Gli-1
both play important roles in cancer progression.
Increased understanding of the importance of stem
cell-related markers allows a more targeted approach to
therapy for individual tumours. Our current study high-
lights the novel therapeutic targeting of distinct onco-
genic signalling elements activated in cancer progenitor
cells and their local microenvironment. In this paper, the
direct effect of CRT for BMI1 expression was not inves-
tigated. Liu et al. have shown that BMI1 expression was
observed in 64.3% of ESCC patients [26], whereas after
CRT, expression was observed in 30.8% of the patients
in our study. These results suggested that persistent
BMI1 expression even after CRT correlated with earlier
relapse and treatment resistance, and that CRT was con-
tributory in eradicating ‘more aggressive’ cancer cells ab-
errantly overexpressing BMI1. This is of great
importance to propose a practical implementation of the
concept of (semi-) personalised treatment in the clinical
field of action.Conclusions
We demonstrated that BMI1 positivity indicative of PcG
protein chromatin silencing pathway activation was sig-
nificantly correlated with oesophageal cancer recurrence
and poor prognosis after CRT, and that it was not
inversely correlated with the presence of the down-
stream target p16INK4A. Although the functional and
clinical significance of the stemness signature, including
components of the Hh and PcG pathways, remain to be
elucidated, we suggest that BMI1 expression along with
Gli-1-positive expression is a link between relapse and
CRT-resistant cancer cells, and is thus a potential prog-
nostic biomarker and rational therapeutic target for
attacking the ‘more aggressive’ cancer cells causing
recurrence and treatment resistance.Abbreviations
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